deferoxamine has been researched along with Adverse Drug Event in 12 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone (L1) has been recommended as an effective oral chelation therapy for patients with beta-thalassemia major (TM)." | 9.12 | Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. ( Hsiao, CC; Jang, RC; Liang, DC; Peng, CT; Wang, LY; Wu, KH; Wu, SF; Yang, CP, 2006) |
| "The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients > or =2 yr with beta-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone." | 5.14 | Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. ( Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A, 2009) |
| "Deferiprone (L1) has been recommended as an effective oral chelation therapy for patients with beta-thalassemia major (TM)." | 5.12 | Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. ( Hsiao, CC; Jang, RC; Liang, DC; Peng, CT; Wang, LY; Wu, KH; Wu, SF; Yang, CP, 2006) |
| "Iron chelating agents - deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX) - are used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to siderosis." | 4.93 | Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. ( El Rassi, F; Saliba, AN; Taher, AT, 2016) |
| " Physiopathologic mechanisms associated with these toxic effects are yet unclear and, besides discontinuation of the drug, when possible, there is no current validated treatment once visual loss is present." | 2.49 | [Ocular toxicity of drugs]. ( Audo, I, 2013) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Geneen, LJ | 1 |
| Dorée, C | 1 |
| Estcourt, LJ | 1 |
| Audo, I | 1 |
| Lamba, N | 1 |
| Anderson-Nelson, S | 1 |
| Saliba, AN | 1 |
| El Rassi, F | 1 |
| Taher, AT | 3 |
| Otto-Duessel, M | 1 |
| Brewer, C | 1 |
| Gonzalez, I | 1 |
| Nick, H | 1 |
| Wood, JC | 1 |
| Porter, JB | 1 |
| Cappellini, MD | 2 |
| Vichinsky, EP | 1 |
| Taher, A | 1 |
| El-Beshlawy, A | 1 |
| Elalfy, MS | 1 |
| Al Zir, K | 1 |
| Daar, S | 1 |
| Habr, D | 1 |
| Kriemler-Krahn, U | 1 |
| Hmissi, A | 1 |
| Al Jefri, A | 1 |
| Musallam, KM | 1 |
| DUGDALE, AE | 1 |
| POWELL, LW | 1 |
| Peng, CT | 1 |
| Wu, KH | 1 |
| Wu, SF | 1 |
| Liang, DC | 1 |
| Yang, CP | 1 |
| Jang, RC | 1 |
| Wang, LY | 1 |
| Hsiao, CC | 1 |
5 reviews available for deferoxamine and Adverse Drug Event
| Article | Year |
|---|---|
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Anemia, Sickle Cell; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Drug-Related Side Eff | 2023 |
[Ocular toxicity of drugs].
Topics: Anticonvulsants; Antimalarials; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Eye I | 2013 |
Medication induced retinal side effects.
Topics: Antimalarials; Canthaxanthin; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Female; | 2014 |
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Mana | 2016 |
Overview of iron chelation therapy with desferrioxamine and deferiprone.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Human | 2009 |
2 trials available for deferoxamine and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxa | 2009 |
Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan.
Topics: Adolescent; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, | 2006 |
5 other studies available for deferoxamine and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Topics: Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Dr | 2008 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side | 2008 |
ACUTE IRON POISONING: ITS EFFECTS AND TREATMENT.
Topics: Chelating Agents; Deferoxamine; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Edeti | 1964 |